These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17328936)

  • 1. Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease.
    Sponseller BA; Sparks WO; Wannemuehler Y; Li Y; Antons AK; Oaks JL; Carpenter S
    Virology; 2007 Jun; 363(1):156-65. PubMed ID: 17328936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection.
    Mealey RH; Leib SR; Pownder SL; McGuire TC
    J Virol; 2004 Sep; 78(17):9295-305. PubMed ID: 15308724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony.
    Leroux C; Issel CJ; Montelaro RC
    J Virol; 1997 Dec; 71(12):9627-39. PubMed ID: 9371627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of equine infectious anemia virus escape from neutralizing antibody responses define epitope specificity.
    Sponseller BA; Clark SK; Friedrich RA
    Viral Immunol; 2012 Aug; 25(4):324-8. PubMed ID: 22746986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication.
    Craigo JK; Leroux C; Howe L; Steckbeck JD; Cook SJ; Issel CJ; Montelaro RC
    J Gen Virol; 2002 Jun; 83(Pt 6):1353-1359. PubMed ID: 12029150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apparent elimination of EIAV ancestral species in a long-term inapparent carrier.
    Craigo JK; Sturgeon TJ; Cook SJ; Issel CJ; Leroux C; Montelaro RC
    Virology; 2006 Jan; 344(2):340-53. PubMed ID: 16226288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony.
    Belshan M; Baccam P; Oaks JL; Sponseller BA; Murphy SC; Cornette J; Carpenter S
    Virology; 2001 Jan; 279(1):185-200. PubMed ID: 11145901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.
    Hammond SA; Li F; McKeon BM; Cook SJ; Issel CJ; Montelaro RC
    J Virol; 2000 Jul; 74(13):5968-81. PubMed ID: 10846078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.
    Howe L; Leroux C; Issel CJ; Montelaro RC
    J Virol; 2002 Nov; 76(21):10588-97. PubMed ID: 12368301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.
    Leroux C; Craigo JK; Issel CJ; Montelaro RC
    J Virol; 2001 May; 75(10):4570-83. PubMed ID: 11312327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes.
    Mealey RH; Sharif A; Ellis SA; Littke MH; Leib SR; McGuire TC
    Virology; 2005 Aug; 339(1):110-26. PubMed ID: 15979679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids.
    Harrold SM; Cook SJ; Cook RF; Rushlow KE; Issel CJ; Montelaro RC
    J Virol; 2000 Apr; 74(7):3112-21. PubMed ID: 10708426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain.
    Howe L; Craigo JK; Issel CJ; Montelaro RC
    J Gen Virol; 2005 Jan; 86(Pt 1):139-149. PubMed ID: 15604441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies.
    Han X; Zhang P; Yu W; Xiang W; Li X
    Virus Genes; 2016 Dec; 52(6):814-822. PubMed ID: 27572122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy.
    Craigo JK; Montelaro RC
    Curr HIV Res; 2010 Jan; 8(1):81-6. PubMed ID: 20210783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Horses naturally infected with EIAV harbor 2 distinct SU populations but are monophyletic with respect to IN.
    Cervantes DT; Ball JM; Edwards J; Payne S
    Virus Genes; 2016 Feb; 52(1):71-80. PubMed ID: 26739458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A unique evolution of the s2 gene of equine infectious anemia virus in hosts correlated with particular infection statuses.
    Wang XF; Wang S; Liu Q; Lin YZ; Du C; Tang YD; Na L; Wang X; Zhou JH
    Viruses; 2014 Nov; 6(11):4265-79. PubMed ID: 25390683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of memory cytotoxic T lymphocytes to equine infectious anemia virus proteins in blood from carrier horses.
    McGuire TC; Zhang W; Hines MT; Henney PJ; Byrne KM
    Virology; 1997 Nov; 238(1):85-93. PubMed ID: 9375012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus.
    Lichtenstein DL; Issel CJ; Montelaro RC
    J Virol; 1996 Jun; 70(6):3346-54. PubMed ID: 8648664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rev variation during persistent lentivirus infection.
    Carpenter S; Chen WC; Dorman KS
    Viruses; 2011 Jan; 3(1):1-11. PubMed ID: 21994723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.